The key translational targets of METTL1 are CXCL8 in humans and CXCL5 in mice, which can facilitate its crucial immunomodulator function in promoting PMN‐MDSC accumulation in the TIME and ICC progression. The gene discussed is CXCL5; the disease is intrahepatic cholangiocarcinoma.